

# Sly Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/S1960EA9CD46EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: S1960EA9CD46EN

## Abstracts

The 7 major Sly syndrome markets reached a value of US\$ 670.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 934.7 Million by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.

The Sly syndrome market has been comprehensively analyzed in IMARC's new report titled "Sly Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sly syndrome, also known as Mucopolysaccharidosis type VII (MPS VII), is a rare and severe inherited metabolic disorder characterized by the deficiency of the enzyme beta-glucuronidase. This enzyme is responsible for breaking down glycosaminoglycans (GAGs) in the body. In Sly syndrome, the absence of functional beta-glucuronidase leads to the progressive accumulation of GAGs in various tissues and organs, resulting in widespread cellular damage and dysfunction. The symptoms of Sly syndrome typically appear in early infancy or childhood and vary in severity. Some of the common clinical manifestations include skeletal abnormalities, such as coarse facial features, joint stiffness, skeletal dysplasia, etc. Various other symptoms may involve hepatosplenomegaly (enlargement of the liver and spleen), cardiomyopathy (heart muscle disease), respiratory issues, and neurological complications like developmental delay, intellectual disability, and behavioral problems. The diagnosis of Sly syndrome involves a combination of clinical evaluation, biochemical testing, and genetic analysis. A physical examination may reveal the characteristic facial features and skeletal abnormalities. Blood and urine tests can detect elevated levels of GAGs, pointing to the presence of mucopolysaccharidosis. Further confirmation is achieved through enzyme activity testing, where the deficiency of beta-glucuronidase is established. Genetic testing is vital for identifying specific mutations in the GUSB gene, which confirms the diagnosis of Sly syndrome and helps

in providing accurate genetic counseling for affected families.

The increasing prevalence of mutations in the GUSB gene, which result in the deficiency of the enzyme beta-glucuronidase, is primarily driving the Sly syndrome market. In addition to this, the expanding utilization of enzyme replacement therapy (ERT), a treatment that involves administering the missing enzyme intravenously, is also creating a positive outlook for the market. ERT aims to replace the deficient enzyme and alleviate the build-up of GAGs in affected tissues, mitigating disease progression and improving patients' quality of life. Furthermore, the widespread adoption of supportive therapies, such as physical and occupational therapies, to address musculoskeletal and neurological issues is also contributing to the market growth. These therapies help in enhancing muscle strength, improving coordination, and enhancing gross motor skills in affected individuals. Apart from this, ongoing advancements in gene therapy, a promising approach involving the introduction of functional genetic material to correct the mutated GUSB gene, hold potential for transformative outcomes in the treatment of Sly syndrome, further driving the market growth during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Sly syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Sly syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Sly syndrome market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States  
Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the Sly syndrome market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the Sly syndrome market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current Sly syndrome marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of

marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the Sly syndrome market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Sly syndrome market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Sly syndrome market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Sly syndrome across the seven major markets?

What is the number of prevalent cases (2018-2034) of Sly syndrome by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Sly syndrome by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Sly syndrome across the seven major markets?

What is the size of the Sly syndrome patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Sly syndrome?

What will be the growth rate of patients across the seven major markets?

Sly Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Sly syndrome drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Sly syndrome market?

What are the key regulatory events related to the Sly syndrome market?

What is the structure of clinical trial landscape by status related to the Sly syndrome market?

What is the structure of clinical trial landscape by phase related to the Sly syndrome market?

What is the structure of clinical trial landscape by route of administration related to the Sly syndrome market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 SLY SYNDROME - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (?2024-2034?)
- 4.4 Market Overview (2018-2023) and Forecast (?2024-2034?)
- 4.5 Competitive Intelligence

### **5 SLY SYNDROME - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 SLY SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (?2024-2034?)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (?2024-2034?)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (?2024-2034?)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (?2024-2034?)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (?2024-2034?)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (?2024-2034?)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (?2024-2034?)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (?2024-2034?)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 SLY SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 SLY SYNDROME - UNMET NEEDS**

## **10 SLY SYNDROME - KEY ENDPOINTS OF TREATMENT**

## **11 SLY SYNDROME - MARKETED PRODUCTS**

- 11.1 List of Sly Syndrome Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Mepsevii (Vestronidase alfa) - Ultragenyx Pharmaceutical
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Market

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.



## **12 SLY SYNDROME - PIPELINE DRUGS**

### 12.1 List of Sly Syndrome Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. SLY SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. SLY SYNDROME – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 SLY SYNDROME - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Sly Syndrome - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (?2024-2034?)

#### 15.2.2 Sly Syndrome - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (?2024-2034?)

### 15.3 Market Scenario - United States

#### 15.3.1 Sly Syndrome - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (?2024-2034?)

#### 15.3.2 Sly Syndrome - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (?2024-2034?)

- 15.3.3 Sly Syndrome - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Sly Syndrome - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (?2024-2034?)
  - 15.4.2 Sly Syndrome - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.4.3 Sly Syndrome - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Sly Syndrome - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (?2024-2034?)
  - 15.5.2 Sly Syndrome - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.5.3 Sly Syndrome - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Sly Syndrome - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (?2024-2034?)
  - 15.6.2 Sly Syndrome - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.6.3 Sly Syndrome - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Sly Syndrome - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (?2024-2034?)
  - 15.7.2 Sly Syndrome - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.7.3 Sly Syndrome - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Sly Syndrome - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (?2024-2034?)
  - 15.8.2 Sly Syndrome - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.8.3 Sly Syndrome - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Sly Syndrome - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (?2024-2034?)
  - 15.9.2 Sly Syndrome - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.9.3 Sly Syndrome - Access and Reimbursement Overview

## **16 SLY SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 SLY SYNDROME MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 SLY SYNDROME MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Sly Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/S1960EA9CD46EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S1960EA9CD46EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

